Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC

Summary

This is a single arm, open label, multi-center, phase 2 study to evaluate the safety and efficacy of sequential treatment with Melphalan/HDS followed by sorafenib in patients with unresectable hepatocellular carcinoma (HCC) confined to the liver.

Timeline

Start

2014-10

Primary completion

2017-12

Completion

2017-12

Outcome

Outcome not reported

Stopped (Enrollment): “No enrollment in the study”

Drugs

Indications